ClinicalTrials.gg
CompletedNCT04392154ADjoinUpdated Nov 5, 2025Results posted

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

A Phase 3 interventional study of Lebrikizumab in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 321 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-11-05.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,153
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.

Enrollment
Largest of 24
1,153 · median 252
Started
2020
with 3 others
Phase 3
17 of 24
2 open now
Registered
8th of 24
by date
Lead sponsor
14 of 24
Eli Lilly and Company

Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one has the largest enrollment, is one of 4 that started in 2020, is one of 17 in phase 3, and was the 8th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing lebrikizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Read the detailed description

Participants who have completed participation in a Dermira- or Lilly-sponsored lebrikizumab study (parent study), DRM06-AD04 (NCT04146363), DRM06-AD05 (NCT04178967), DRM06-AD06 (NCT04250337), DRM06-AD17 (NCT04250350) or DRM06- AD18 (NCT04626297), will be offered the opportunity to enroll in this study. Participants may either be blinded or not blinded, depending on their parent study assignment.

This study will also be open to an additional approximately 100 participants in the United States (addendum) who have not completed participation in a Dermira- or Lilly-sponsored lebrikizumab study. Treatment will not be blinded.

This study will also include an Addendum to extend the study treatment period by an additional 32 weeks and to add a treatment arm testing dosing every 8 weeks. This Addendum will apply to existing study participants in selected countries. Treatment will not be blinded.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Eczema
  • Dermatitis
  • Dermatitis, Atopic
  • Skin Diseases
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for participants coming from a parent study:

Participants must meet all the following criteria to be eligible for this study:

  • Received treatment in a lebrikizumab study, NCT04146363, NCT04178967, NCT04250337, NCT04250350 and have adequately completed the study treatments and last patient visit of the parent trial.
  • For women of : agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective method during the treatment period and for at least 18 weeks after the last dose of lebrikizumab or placebo.

Exclusion Criteria for participants coming from a parent study:

Participants meeting any of the criteria below will not be included in this study:

  • Participants who, during their participation in the parent trial, developed a serious adverse event (SAE) deemed related to lebrikizumab, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the participant. *
  • Participants who, during their participation in the parent trial, developed an AE that was deemed related to lebrikizumab and led to study treatment discontinuation, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the participant. *
  • Conditions in the previous parent study consistent with protocol-defined criteria for permanent study drug discontinuation, if deemed related to lebrikizumab or led to investigator - or sponsor-initiated withdrawal of participant from the study (e.g., non-compliance, inability to complete study assessments, etc.). *
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.

Open-Label Addendum Inclusion Criteria:

Participants must meet all the following criteria to be eligible for this study addendum:

  • Male or female adults and adolescents (≥12 to \<18 years of age and weighing ≥40 kilogram (kg).
  • Chronic AD (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before screening.
  • Eczema Area and Severity Index (EASI) score ≥16 at baseline.
  • Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at baseline.
  • ≥10% body surface area (BSA) of AD involvement at baseline.
  • History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable.

Open-Label Addendum Exclusion Criteria:

Participants meeting any of the criteria below will be excluded from this study addendum:

  • Have received a dose of lebrikizumab in any prior lebrikizumab clinical study.
  • History of anaphylaxis
  • Treatment with topical prescription moisturizers, , calcineurin inhibitors, or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to baseline.
  • Treatment with any of the following agents within 4 weeks prior to the baseline.

    • /immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, Interferon gamma (IFN-γ), Janus kinase inhibitors, azathioprine, methotrexate, etc.)
    • Phototherapy and photochemotherapy (PUVA) for AD.
  • Treatment with the following prior to baseline:

    • Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)
    • Phototherapy and photochemotherapy (PUVA) for AD.
  • Treatment with the following prior to baseline:

    • An drug within 8 weeks or within 5 half-lives (if known), whichever is longer.
    • B Cell-depleting biologics, including rituximab, within 6 months.
    • Other Biologics within 5 half-lives (if known) or 8 weeks, whichever is longer.
  • Regular use (more than 2 uses per week) of a tanning booth/parlor within 4 weeks of baseline.
  • Treatment with a live (attenuated) vaccine within 12 weeks of the baseline or planned during the study.
  • Uncontrolled chronic disease that might require multiple intermittent uses of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma, (as defined by the investigator).
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.
  • Evidence of active acute or chronic hepatitis
  • History of (HIV) infection or positive HIV serology at screening.
  • History of , including mycosis fungoides, within 5 years before screening, except completely treated in situ carcinoma of the cervix, completely treated and resolved non- squamous or basal cell carcinoma of the skin with no evidence of recurrence in the past 12 weeks.

Open-Label Extension Addendum Inclusion Criteria:

Have completed Week 100 of Study KGAA and have not yet completed the safety follow-up visit for the main study.

Open-Label Extension Addendum Exclusion Criteria:

Have initiated treatment with a medication prohibited by Study KGAA before addendum baseline. This includes use of biologics for AD (for example, dupilumab and tralokinumab) during the safety follow-up period of Study KGAA.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,153 participants (actual)

Study arms

  • Experimental
    Lebrikizumab Q2W (Primary Treatment Period)

    250 milligrams (mg) of Lebrikizumab, subcutaneous injection administered every 4 weeks (Q4W) up to 100 weeks.

    Biological: Lebrikizumab

  • Experimental
    Lebrikizumab Q4W (Primary Treatment Period)

    250 mg Lebrikizumab, subcutaneous injection administered every 2 weeks (Q2W) up to 100 weeks.

    Biological: Lebrikizumab

  • Experimental
    Open-Label Extension Addendum: Lebrikizumab Q4W

    250 mg of Lebrikizumab, subcutaneous injection administered every 4 weeks (Q4W) up to 32 weeks.

    Biological: Lebrikizumab

  • Experimental
    Open-Label Extension Addendum: Lebrikizumab Q8W

    250 mg of Lebrikizumab, subcutaneous injection administered every 8 weeks (Q8W) up to 32 weeks.

    Biological: Lebrikizumab

Interventions

  • BiologicalLebrikizumab

    Subcutaneous injection

    Also known as: LY3650150, DRM06

06

What researchers measure

Primary outcomes

  1. Primary Treatment Period: Percentage of Participants Discontinued From Study Treatment Due to Adverse Events

    Percentage of participants discontinued from study treatment due to adverse events is reported.

    Time frame: Baseline to Week 100

Secondary outcomes

  1. Primary Treatment Period: Percentage of Participants With a Response of Investigator Global Assessment (IGA) Score 0 or 1 at Week 100

    The IGA measures the investigator's global assessment of the participant's overall severity of their Atopic Dermatitis. The IGA is comprised of a 5-point numeric scale ranging from 0 (clear skin) to 4 (severe disease) and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point.

    Time frame: Week 100

  2. Primary Treatment Period: Percentage of Participants Achieving Response of Eczema Area and Severity Index-75 (EASI-75) at Week 100

    EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity.

    Time frame: Week 100

07

Results

Posted Aug 3, 2025

Participant flow

This study consists of 2 parts: * 100-week primary treatment period where participants were assigned to either Lebrikizumab Q4W or Q2W treatment arms. * 32-week open label extension addendum (Lebrikizumab Q4W and Lebrikizumab Q8W)

Primary Treatment Period (100 Weeks)
Participant flow — Primary Treatment Period (100 Weeks)
MilestonePrimary Treatment Period: Lebrikizumab Q4WPrimary Treatment Period: Lebrikizumab Q2WOpen-Label Extension Addendum: Lebrikizumab Q4WOpen-Label Extension Addendum: Lebrikizumab Q8W
Started141101200
Received at least 1 dose of study drug141101200
Completed10367500
Not completed3833700
Withdrew: Adverse event34600
Withdrew: Due to epidemic/pandemic0100
Withdrew: Lack of efficacy14700
Withdrew: Lost to follow-up116100
Withdrew: Geopolitical conflict1100
Withdrew: Physician decision1500
Withdrew: Pregnancy1800
Withdrew: Protocol deviation11200
Withdrew: Withdrawal by subject1813800
Withdrew: Sponsor decision11400
Withdrew: Site closure0400
Open-Label Extension Addendum (32 Weeks)
Participant flow — Open-Label Extension Addendum (32 Weeks)
MilestonePrimary Treatment Period: Lebrikizumab Q4WPrimary Treatment Period: Lebrikizumab Q2WOpen-Label Extension Addendum: Lebrikizumab Q4WOpen-Label Extension Addendum: Lebrikizumab Q8W
Started005251
Received at least one doe of study drug005251
Completed005149
Not completed0012
Withdrew: Lost to follow-up0001
Withdrew: Protocol deviation0010
Withdrew: Withdrawal by subject0001

Outcome measures

PrimaryPrimary Treatment Period: Percentage of Participants Discontinued From Study Treatment Due to Adverse Events

Percentage of participants discontinued from study treatment due to adverse events is reported.

Time frame:
Baseline to Week 100
Reported as:
Number · percentage of participants
Primary Treatment Period: Percentage of Participants Discontinued From Study Treatment Due to Adverse Events
percentage of participantsPrimary Treatment Period: Lebrikizumab Q4WPrimary Treatment Period: Lebrikizumab Q2W
Primary Treatment Period: Percentage of Participants Discontinued From Study Treatment Due to Adverse Events2.14.5
SecondaryPrimary Treatment Period: Percentage of Participants With a Response of Investigator Global Assessment (IGA) Score 0 or 1 at Week 100

The IGA measures the investigator's global assessment of the participant's overall severity of their Atopic Dermatitis. The IGA is comprised of a 5-point numeric scale ranging from 0 (clear skin) to 4 (severe disease) and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point.

Time frame:
Week 100
Reported as:
Number · Percentage of participants
Primary Treatment Period: Percentage of Participants With a Response of Investigator Global Assessment (IGA) Score 0 or 1 at Week 100
Percentage of participantsPrimary Treatment Period: Lebrikizumab Q4WPrimary Treatment Period: Lebrikizumab Q2W
Primary Treatment Period: Percentage of Participants With a Response of Investigator Global Assessment (IGA) Score 0 or 1 at Week 10080.160.6
SecondaryPrimary Treatment Period: Percentage of Participants Achieving Response of Eczema Area and Severity Index-75 (EASI-75) at Week 100

EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity.

Time frame:
Week 100
Reported as:
Number · Percentage of participants
Primary Treatment Period: Percentage of Participants Achieving Response of Eczema Area and Severity Index-75 (EASI-75) at Week 100
Percentage of participantsPrimary Treatment Period: Lebrikizumab Q4WPrimary Treatment Period: Lebrikizumab Q2W
Primary Treatment Period: Percentage of Participants Achieving Response of Eczema Area and Severity Index-75 (EASI-75) at Week 10090.479.4

Adverse events

Collected over Primary Treatment Period: Up to 110 Weeks; Open-Label Extension Addendum: up to 42 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Primary Treatment Period: Lebrikizumab Q4W0/141 (0%)5/141 (3.5%)89/141 (63.1%)
Primary Treatment Period: Lebrikizumab Q2W2/1,012 (0.2%)45/1,012 (4.4%)638/1,012 (63%)
Open-Label Extension Addendum: Lebrikizumab Q4W0/52 (0%)0/52 (0%)17/52 (32.7%)
Open-Label Extension Addendum: Lebrikizumab Q8W0/51 (0%)0/51 (0%)13/51 (25.5%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventPrimary Treatment Period: Lebrikizumab Q4WPrimary Treatment Period: Lebrikizumab Q2WOpen-Label Extension Addendum: Lebrikizumab Q4WOpen-Label Extension Addendum: Lebrikizumab Q8W
Food allergyImmune system disorders1/1410/10120/520/51
CellulitisInfections and infestations1/1410/10120/520/51
AccidentInjury, poisoning and procedural complications1/1410/10120/520/51
Hip fractureInjury, poisoning and procedural complications1/1412/10120/520/51
Multiple injuriesInjury, poisoning and procedural complications1/1410/10120/520/51
DepressionPsychiatric disorders1/1411/10120/520/51
AppendicitisInfections and infestations0/1412/10120/520/51
PneumoniaInfections and infestations0/1412/10120/520/51
Ankle fractureInjury, poisoning and procedural complications0/1412/10120/520/51
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1412/10120/520/51
Most frequent other events
Showing 10 of 554
Most frequent other events
EventPrimary Treatment Period: Lebrikizumab Q4WPrimary Treatment Period: Lebrikizumab Q2WOpen-Label Extension Addendum: Lebrikizumab Q4WOpen-Label Extension Addendum: Lebrikizumab Q8W
Covid-19Infections and infestations26/141159/10121/520/51
NasopharyngitisInfections and infestations13/141115/10122/520/51
Dermatitis atopicSkin and subcutaneous tissue disorders9/14170/10120/521/51
Upper respiratory tract infectionInfections and infestations7/14149/10121/520/51
ConjunctivitisInfections and infestations3/14139/10121/520/51
Oral herpesInfections and infestations2/14130/10120/520/51
Urinary tract infectionInfections and infestations3/14130/10120/521/51
Conjunctivitis allergicEye disorders4/14129/10120/520/51
SinusitisInfections and infestations4/14115/10120/520/51
HeadacheNervous system disorders4/14125/10121/521/51

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Primary Treatment Period: Lebrikizumab Q4WPrimary Treatment Period: Lebrikizumab Q2WTotal
Mean34.9 ± 16.9632.5 ± 17.2332.8 ± 17.21
Sex: Female, Male
Sex: Female, Male(Participants)Primary Treatment Period: Lebrikizumab Q4WPrimary Treatment Period: Lebrikizumab Q2WTotal
Female82513595
Male59499558
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Primary Treatment Period: Lebrikizumab Q4WPrimary Treatment Period: Lebrikizumab Q2WTotal
American Indian or Alaska Native11617
Asian21199220
Native Hawaiian or Other Pacific Islander1910
Black or African American9138147
White106610716
More than one race32528
Unknown or Not Reported01515
Region of Enrollment
Region of Enrollment(Participants)Primary Treatment Period: Lebrikizumab Q4WPrimary Treatment Period: Lebrikizumab Q2WTotal
Singapore178
United States72591663
Ukraine549
Spain077
Canada148094
Latvia358
South Korea22527
Taiwan45155
Poland23135158
Mexico224
Australia32326
Bulgaria01010
France134
Lithuania11213
Germany105262
Estonia055
08

Study locations

321 sites
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
  • Clinical Research Center of Alabama- Birmingham
    Birmingham, Alabama 35244, United States
  • Investigate MD
    Scottsdale, Arizona 85255, United States
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Arkansas Research Trials
    North Little Rock, Arkansas 72117, United States
  • Northwest Arkansas Clinical Trials Center
    Rogers, Arkansas 72758, United States
  • Orange County Research Institute
    Anaheim, California 92801, United States
  • Bakersfield Dermatology and Skin Cancer Medical Group
    Bakersfield, California 93309, United States
  • Wallace Medical Group, Inc.
    Beverly Hills, California 90211, United States
  • Hope Clinical Research, Inc.
    Canoga Park, California 91303, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • MD Studies
    Fountain Valley, California 92708, United States
  • Center For Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Axon Clinical Research
    Inglewood, California 90301, United States
  • Sunwise Clinical Research
    Lafayette, California 94549, United States
  • Avance Clinical Trials Inc
    Laguna Niguel, California 92677, United States
  • California Allergy and Asthma Medical Group + Research Center
    Los Angeles, California 90025, United States
  • Keck School of Medicine University of Southern California
    Los Angeles, California 90033, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • LA Universal Research Center, INC
    Los Angeles, California 90057, United States
  • Ablon Skin Institute and Research Center
    Manhattan Beach, California 90266, United States
  • Dermatology Clinical Trials
    Newport Beach, California 92660, United States
  • Cura Clinical Research
    Palmdale, California 93551, United States
  • MD Strategies Research Centers MDSRC
    Poway, California 92064, United States
  • Integrative Skin Science and Research
    Sacramento, California 95815, United States
  • Integrative Skin Science and Research
    Sacramento, California 95825, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • University Clinical Trials
    San Diego, California 92123, United States
  • University of California, San Diego/Rady Children's Hospital, San Diego - Pediatric & Adolescent Dermatology
    San Diego, California 92123, United States
  • Synergy Dermatology
    San Francisco, California 94132, United States
  • Care Access Research
    San Jose, California 95117, United States
  • San Luis Dermatology & Laser Clinic
    San Luis Obispo, California 93405, United States
  • Southern California Dermatology, Inc.
    Santa Ana, California 92701, United States
  • IMMUNOe International Research Centers
    Centennial, Colorado 80112, United States
  • Asthma and Allergy Associates, PC
    Colorado Springs, Colorado 80907-6231, United States
  • Central Connecticut Dermatology
    Cromwell, Connecticut 06416, United States
  • Medical Faculty Associates, Inc.
    Washington D.C., District of Columbia 20016, United States
  • George Washington University Medical Center
    Washington D.C., District of Columbia 20037, United States
  • St. Francis Medical Institute
    Clearwater, Florida 33765, United States
  • Florida Academic Centers Research and Education, LLC
    Coral Gables, Florida 33134, United States
  • Pediatric Skin Research, LLC
    Coral Gables, Florida 33146, United States
  • Clinical Physiology Associates
    Fort Myers, Florida 33912, United States
  • The University of Florida Health System
    Gainesville, Florida 32606, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • The Community Research of South Florida
    Hialeah, Florida 33016, United States
  • Encore Medical Research
    Hollywood, Florida 33021, United States
  • Solutions Through Advanced Research
    Jacksonville, Florida 32256, United States
  • GSI Clinical Research, LLC
    Margate, Florida 33063, United States
  • Vitae Research Center, LLC
    Miami, Florida 33135, United States
  • Acevedo Clinical Research Associates
    Miami, Florida 33142, United States
  • International Dermatology Research, Inc.
    Miami, Florida 33144, United States
  • Community Research Foundation Inc
    Miami, Florida 33145, United States
  • Sanchez Clinical Research Inc
    Miami, Florida 33157, United States
  • Miami Dermatology and Laser Research
    Miami, Florida 33173, United States
  • Well Pharma Medical Research Corp.
    Miami, Florida 33173, United States
  • Florida Research Center, Inc
    Miami, Florida 33174, United States
  • C & R Research Services USA
    Miami Beach, Florida 33169, United States
  • Wellness Clinical Research
    Miami Lakes, Florida 33016, United States
  • Tory Sullivan, MD PA
    North Miami Beach, Florida 33162, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • Riverchase Dermatology and Cosmetic Surgery
    Pembroke Pines, Florida 33028, United States
  • ForCare Clinical Research
    Tampa, Florida 33613-1244, United States
  • Olympian Clinical Research
    Tampa, Florida 33614, United States
  • University of South Florida College of Medicine
    Tampa, Florida 33620, United States
  • Georgia Pollens Clinical Research Centers, Inc
    Albany, Georgia 31707, United States
  • IACT Health - VHC
    Columbus, Georgia 31904, United States
  • Marietta Dermatology Clinical Research
    Marietta, Georgia 30060, United States
  • Advanced Medical Research
    Sandy Springs, Georgia 30328, United States
  • Georgia Skin & Cancer Clinic
    Savannah, Georgia 31419, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Sneeze, Wheeze, & Itch Associates LLC
    Normal, Illinois 61761, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • Northshore University Healthsystem
    Skokie, Illinois 60077, United States
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Epiphany Dermatology of Kansas, LLC
    Overland Park, Kansas 66210, United States
  • Kansas Medical Clinic, an Elligo Health Research, Inc.
    Shawnee Mission, Kansas 66216, United States
  • Kansas Medical Clinic
    Topeka, Kansas 66614, United States
  • Skin Sciences, PLLC
    Louisville, Kentucky 40217, United States
  • Meridian Clinical Research
    Baton Rouge, Louisiana 70808, United States
  • Tulane Univ School of Med
    New Orleans, Louisiana 70112, United States
  • Dermatology and Skin Cancer Specialists, LLC
    Rockville, Maryland 20850, United States
  • ActivMed Practices and Research
    Beverly, Massachusetts 01915, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Metro Boston Clinical Partners
    Brighton, Massachusetts 02135, United States
  • Beacon Clinical Research, LLC
    Quincy, Massachusetts 02169, United States
  • Fivenson Dermatology
    Ann Arbor, Michigan 48103, United States
  • Oakland Dermatology
    Auburn Hills, Michigan 48326, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • Michigan Center for Research Company
    Clarkston, Michigan 48346, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • St Joseph Dermatology and Vein Clinic
    Saint Joseph, Michigan 49085, United States
  • Associated Skin Care Specialists
    Fridley, Minnesota 55432, United States
  • Associated Skin Care Specialists
    New Brighton, Minnesota 55112, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Central Dermatology PC
    St Louis, Missouri 63117, United States

Showing the first 100 of 321 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Guttman-Yassky E, Irvine AD, Gooderham M, Weidinger S, Spelman L, Silverberg JI, Crane H, ElMaraghy H, DeLuca-Carter L, Piruzeli MLB, Martimianaki G, Pierce E, Agell H, Thaci D. Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin). Dermatol Ther (Heidelb). 2026 Jun 19. doi: 10.1007/s13555-026-01810-1. Online ahead of print. PubMed 42315763 ↗
  • Silverberg JI, Wollenberg A, Stein Gold L, Yosipovitch G, Lio P, Vestergaard C, Stander S, Carrascosa JM, Gallo G, Casillas M, Ding Y, Yang FE, Pierce E, Agell H, Del Rosso J. Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis. Clin Exp Dermatol. 2026 May 26;51(6):1012-1019. doi: 10.1093/ced/llaf490. PubMed 41206702 ↗
  • Guttman-Yassky E, Weidinger S, Simpson EL, Gooderham M, Irvine AD, Spelman L, Silverberg JI, ElMaraghy H, DeLuca-Carter L, Piruzeli MLB, Hu C, Yang FE, Pierce E, Bardolet L, Thaci D. Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin). Dermatol Ther (Heidelb). 2025 Aug;15(8):2217-2232. doi: 10.1007/s13555-025-01452-9. Epub 2025 Jun 23. PubMed 40549127 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jul 2024, 49 months.

Results were first posted in Aug 2025, 1 year after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 49 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2020
First posted
May 18, 2020
StartActual
Jun 15, 2020
Primary completionActual
Jul 19, 2024
CompletionActual
Apr 22, 2025
Results first posted
Aug 3, 2025
Last update
Nov 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04392154
Collaborators
Dermira, Inc.
Responsible party
Sponsor
First posted
May 18, 2020
Start date
Jun 15, 2020
Primary completion
Jul 19, 2024
Completion
Apr 22, 2025
Results posted
Aug 3, 2025
Last update
Nov 5, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion